Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Persbericht

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,879   +0,008   (+0,92%) Dagrange 0,874 - 0,882 471.621   Gem. (3M) 6,2M

Persbericht

Volgen
5 Posts
| Omlaag ↓
  1. frederic_knight 24 april 2006 08:32
    DNage, Loders Croklaan, BG Medicine And Erasmus MC Announce Collaboration In Field Of Type II Diabetes
    Department of Economic Affairs grants 1 million Euro subsidy

    Leiden, The Netherlands, April 24, 2006. DNage BV (“DNage”), Loders Croklaan BV, through its wholly owned subsidiary Lipid Nutrition BV (“Lipid Nutrition”), BG Medicine Inc (“BG Medicine”) and the Erasmus University Medical Center (“Erasmus MC”) today announced the start of a collaboration to develop new products and biomarkers for type II diabetes, a frequently occurring metabolic disorder most prevalent in elderly people. A large portion of the research phase of the program during the first three years will be covered by a 1 million Euro grant from the Dutch governmental organization Senter Novem, an agency of the Dutch Ministry of Economic Affairs.

    Under the research collaboration parties intend to validate technology owned by DNage and Erasmus MC for testing products to treat type II diabetes. Lipid Nutrition owns proprietary products potentially useful in dietary management of this disease which will be tested under the program. Another important goal of the collaboration is to identify biomarkers, simple screening tests, to be able to diagnose patients in a very early phase thereby improving chances of successful therapy. This part of the program will make use of proprietary knowledge (systems pathology and systems pharmacology) platforms owned by BG Medicine, combined with tools and intellectual property owned by the other parties.

    After successful completion of the research phase, parties will enter into a commercialization agreement, the principles of which have been agreed upon already. Lipid Nutrition will obtain royalty-bearing rights for nutritional products, DNage will obtain similar rights for pharmaceutical products and BG Medicine will obtain such rights for biomarkers.

    Diabetes mellitus type II is a typical ageing disease which is considered to be the health care challenge of the 21st century. Globally over 180 million people suffer from diabetes as a consequence of ageing and obesity. This number is expected to increase with about 10 million per year. In the Netherlands, the amount of diabetes patients is ~500,000 and also growing. The WHO and the International Diabetes Foundation predict that the number of diabetics worldwide will more than double to 366 million by 2030. There is a large need for new approaches in preventing and treating this disease.

    DNage and Pharming Group NV (“Pharming”), (Euronext: PHARM), (PHARM.AS) recently announced that Pharming intends to acquire all outstanding shares of DNage. This transaction is expected to be completed in May after which the DNage rights and obligations under the newly announced collaboration will be taken over by Pharming.
  3. [verwijderd] 24 april 2006 09:07
    het betekend meer potentieel.
    voor de rest nog niet zo veel.
    Ik denk echter dat de heren niet echt blij zijn dat ze dit hebben moeten melden.
    Dat zet de concurrentie op het vinkentouw.
    En je kan er bijna donder op zeggen dat met de pharming techniek, dit medicijn een vrij goede kans van slagen gaat hebben.
    Daarnaast, focus op rhucin, is niet echt meer nodig.
    Daar houd je al die biotechneuten niet meer mee bezig, want die waren er anderhalf jaar geleden al mee klaar.
    Alleen die boekhouders van deze wereld, die schieten niet echt op.
  5. yinx 24 april 2006 22:24
    Pharming – What DNage can do for Pharming
    Rating: BUY Price Target: €5.50 Closing price: €3.82 volgens Kempen op 24-4-2006

    DNage, a company in the process of being acquired by Pharming, announced that it has entered a collaboration to
    develop new products and biomarkers (simple screening tests) for type II diabetes, a frequently occurring metabolic
    disorder most prevalent in elderly people. DNage will team up Lipid Nutrition (subsidiary of Loders Croklaan, active in
    nutrition), BG Medicine (biomarkers) and Erasmus University Medical Center (major shareholder DNage) and will be
    primarily funded by a €1m grant from the Dutch government for the coming three years.
    The collaboration will use DNage’s animal models to test both nutritional and pharmaceutical products and to identify
    biomarkers for type II diabetes. After the research phase, the collaboration will enter into a commercial agreement,
    whereby Lipid Nutrition will obtain the right for nutritional products, DNage for pharmaceutical products and BG
    Medicine for biomarkers.
    We view this collaboration as the first evidence of what DNage can bring to the table what Pharming was lacking,
    namely deals. We expect that DNage should be able to sign more lucrative deals, as its proprietary technology platform
    is one-of-a-kind, while age related diseases are very compelling as a pharma target. We reiterate our €5.5 price target
    and Buy recommendation.
5 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Pharming stemt over nieuwe CEO
  2. Pharming presenteert nieuwe CEO
  3. Fundlogic verkoopt bijna geheel belang in Pharming
  4. Fundlogic flink groter in Pharming
  5. DWS meldt groter belang in Pharming
  6. Morgan Stanley groter in Pharming
  7. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  8. RBC verhoogt koersdoel Pharming fors
  9. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  10. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster